-CIMT is Used as a Tool for Atherosclerosis-Related Event Prediction and for the Evaluating Atherosclerosis Progression/Regression by Dr. Amjad AlMahameed

Pathophysiology & Epidemiology

      -Of Strokes Source: Merck Inc.

RESPECT: Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment

      -Final Results with Primary End Point Analyses by Dr. John D. Carroll (TCT 2012)


ROCKET-AF: Stroke Prevention Using the Oral Direct Factor Xa Inhibitor Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation

   -Trial Overview by Dr. Kenneth Mahaffey and Dr. Keith Fox (AHA 2010)


VTE and Stroke

      -A Deadly Combination by Dr. Amjad AlMahameed

Who Are We?    Slide Downloading Policy   Financial Disclosure    We Do Not Promote Off Label Product Use    Copyright    Source of Slides    Editorial Policy    Links Policy    Privacy Policy   Access    CME Programs

© 1999-2009 by Clinical Trial Results .org.  None of the materials on this website may be reproduced, modified, distributed, transmitted, republished, displayed, or performed unless prior written approval is obtained by Clinical Trial Results.  All such requests should be forwarded to Susan J. Marble at For further information please see the Policy section. Webmaster